The Simply Good Foods news

The company failed to disclose material information about a significant product quality issue in its OWYN acquisition, resulting in a 27% stock decline, $187 million impairment charge, and substantial downward revision of 2026 guidance. This represents corporate malfeasance and breach of fiduciary duty to shareholders.

The company is the subject of a class action lawsuit alleging material misstatements and omissions regarding the OWYN acquisition, including loss of key personnel, product quality issues, margin erosion, failed strategic goals, and operational problems. These allegations suggest significant corporate governance and operational failures that negatively impacted shareholder value.

Company faces securities fraud allegations involving material misstatements about OWYN acquisition integration, loss of key personnel, product quality problems, unsustainable promotional discounting, and failure to achieve strategic objectives, resulting in investor damages.

Company is subject to securities class action lawsuit alleging material misstatements and omissions regarding failed OWYN acquisition integration, loss of key personnel, product quality deterioration, margin erosion, and failure to achieve strategic objectives.

The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding the failed OWYN acquisition, including loss of key personnel, product quality issues, margin erosion, and failure to achieve strategic objectives. These allegations indicate significant operational and financial problems.

The company is the defendant in a securities class action lawsuit alleging material misstatements and omissions regarding a failed acquisition. The allegations include loss of key personnel, product quality deterioration, margin erosion, and failure to achieve strategic objectives, all of which negatively impact investor confidence and shareholder value.

Company is subject to securities fraud allegations for making materially false statements about OWYN acquisition integration, concealing product quality issues, and failing to disclose operational challenges. Stock declined 17% on October 23, 2025 and 27% on April 10, 2026 following negative earnings revelations.

The company is the subject of a securities fraud class action lawsuit alleging material misstatements and omissions regarding the failed OWYN acquisition. Stock prices fell 17.35% and 18.11% on two separate earnings announcements, a $187 million impairment charge was taken, and 2026 guidance was slashed to negative 7-10% sales growth, indicating severe operational and financial deterioration.

The company faces a securities fraud class action lawsuit alleging material misstatements and omissions regarding the failed OWYN acquisition, including concealment of personnel losses, product quality issues, operational problems, and failure to achieve strategic and financial targets. These allegations indicate significant corporate governance failures and investor deception.

The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding failed acquisition integration, product quality problems, operational inefficiencies, and failure to achieve strategic objectives. These allegations indicate significant corporate governance and operational failures that negatively impacted investor value.

The company is accused of making materially false and misleading statements regarding the OWYN acquisition, including concealing loss of key personnel, product quality problems, inefficient cost structure, failed sales strategies, and overall failure to achieve acquisition objectives. These allegations suggest significant operational and financial mismanagement.

The company faces a class action lawsuit alleging material misstatements and omissions regarding its OWYN acquisition. Undisclosed product quality issues, loss of key personnel, failed integration, and significant operational problems led to substantial stock price declines (17% and 27%) and a $187 million impairment charge, indicating serious business deterioration and investor harm.

The company is accused of securities fraud involving material misstatements about its OWYN acquisition integration. Allegations include undisclosed management departures, organizational dysfunction, quality control problems, and margin erosion. Stock price fell 27% when actual performance (17% OWYN sales decline) contradicted prior positive guidance.

The company is accused of making materially false and misleading statements regarding the OWYN acquisition, concealing product quality issues, personnel losses, and operational failures. Significant stock price declines (17% and 27%) and a $187 million impairment charge demonstrate severe financial and operational deterioration.

Company faces securities class action lawsuit for material non-disclosure regarding product quality issues in acquired OWYN segment, resulting in significant stock price declines (17% and 27%), $187 million impairment charge, and negative sales guidance for 2026.

The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding failed acquisition integration, loss of key personnel, product quality deterioration, margin erosion, and failure to achieve strategic objectives. These allegations suggest significant operational and financial problems that harmed investor value.

The article is a routine earnings announcement with no material business updates, challenges, or achievements mentioned. It is purely informational about the timing and logistics of the earnings call.

While the director's discretionary purchase signals insider confidence in the company's brands (Quest and Atkins), the stock's 65.5% decline over the past year suggests underlying fundamental challenges. The article emphasizes that investors should wait for upcoming earnings to determine if the pressure is structural or cyclical before making investment decisions. The insider buy is noted but not presented as a strong buy signal without further due diligence.

Company reported poor retail performance, slower consumption velocity, missed expectations, reduced full-year guidance significantly (7-10% net sales decline, 19-22% EBITDA decline), and took a substantial $249 million impairment charge. Stock price fell 18.1% on the announcement, triggering a securities investigation.

The company experienced significant stock price declines (17.35% and 18.1%) following disclosure of quality issues with the OWYN brand acquisition, poor retail performance, substantial impairment charges ($249 million), and a major net loss ($159.7 million), prompting a securities fraud investigation.

Company reported poor retail takeaway, reduced full-year guidance significantly (7-10% net sales decline, 19-22% EBITDA decline), took a $249 million impairment charge, and stock price fell 18.1%. Additionally, securities law violations are being investigated.

The company is under investigation for potential securities fraud and issued significantly negative guidance with forecasted 10% sales decline and major EBITDA contraction, resulting in an 18.1% stock price drop.

Stock declined 11.53% following weak Q2 2026 earnings results. Key analyst Ben Bienvenu downgraded from buy to hold and slashed price target by 42% (from $24 to $14), citing soft consumption across all brands, distribution challenges, and poor product innovation. Multiple analysts issued bearish takes post-earnings.

The company faces securities fraud investigation due to misleading statements about product expansion success. Stock dropped 18% following disclosure of product quality problems, poor marketing execution, significant revenue decline (9.4% YoY), negative guidance revision (-10% to -7%), and a substantial $249 million impairment charge.

Stock dropped 18% due to significant earnings miss with sales falling 9.4% YoY versus 3.5-4.5% guidance, major brand declines (Atkins -26.6%, OWYN -16.8%), gross margin compression of 4.6 percentage points, and substantially reduced full-year guidance for both revenue (down to 10% decline) and EBITDA (down ~20%). Despite favorable market trends for high-protein products, the company's brands are not resonating with consumers.

Congressman purchased shares as part of his small-cap stock buying activity, but no specific performance data or company-specific news is provided in the article to determine positive or negative sentiment.

The appointment of an experienced investor relations executive with strong credentials is a routine organizational move. While it demonstrates continuity and brings relevant expertise, it is a standard personnel transition without indication of material business impact or strategic changes.

Securities fraud class action related to undisclosed acquisition failures resulting in over 27% stock decline, indicating significant investor losses from corporate misrepresentation.

Company faces securities fraud class action lawsuit related to undisclosed acquisition failures, resulting in over 27% stock decline and investor losses.

Subject of a securities class action lawsuit with an October 13 deadline for lead plaintiff selection, indicating investor allegations of securities violations, though specific details are not provided in the article excerpt.

Subject of a securities class action lawsuit with an upcoming lead plaintiff deadline, suggesting alleged securities violations or investor harm, though specific allegations are not detailed in the excerpt.

Subject of a securities class action lawsuit, indicating alleged misconduct or misrepresentation to investors.

Subject of a securities class action lawsuit filed by Rosen Law Firm, indicating alleged misconduct or misrepresentation to investors.

Stock dropped 18% on earnings miss with revenue 5% below forecast and 9.45% YoY decline. Company cut full-year guidance from -2% to 2% range to -7% to -10%. Quest brand growth slowing due to competition, Atkins brand declining due to GLP-1 drug competition, and rising production costs eroding margins. Analyst price targets likely to be lowered with UBS already cutting target from $23 to $16.

The stock has declined 53% over the past 52 weeks and is down 15% year-to-date in 2026, indicating significant weakness. Moore is the first congressman to buy it in recent years, suggesting limited institutional confidence.